Combivir

BACKGROUND MERIT was a randomized trial comparing maraviroc (MVC) + Combivir versus efavirenz (EFV) + Combivir in drug-naive… Expand

Abstract Adherence may be facilitated by reducing perceptual and practical barriers to antiretroviral therapy (ART). Practical… Expand

OBJECTIVE To determine the impact of once-nightly versus twice-daily dosing and beliefs about highly active antiretroviral… Expand

Neil Martinson and colleagues report a randomized trial of adding short-course zidovudine+lamivudine to reduce drug resistance… Expand

Combivir is a fixed dose combination tablet of two antiretroviral drugs; zidovudine and lamivudine, used in the treatment of HIV… Expand

OBJECTIVES To compare the lipid and metabolic effects, efficacy, and safety of twice-daily regimens of Trizivir (abacavir 300 mg… Expand

OBJECTIVE Although most uninfected infants born to women infected with HIV-1 show no clinical evidence of mitochondrial… Expand

OBJECTIVE:Preliminary reports suggest that patients with primary biliary cirrhosis (PBC) have evidence of human betaretrovirus… Expand

OBJECTIVE HIV-1 protease inhibitors (versus no protease inhibitors) and stavudine (versus zidovudine) are independently… Expand

BACKGROUND Non-nucleoside reverse transcriptase inhibitor-containing regimens may be a valid alternative to protease inhibitor… Expand